StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays cut their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Stock Down 4.1 %

Shares of Cellectis stock opened at $1.85 on Wednesday. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company’s 50 day moving average is $1.85 and its 200 day moving average is $2.01. The company has a market cap of $102.83 million, a price-to-earnings ratio of -1.42 and a beta of 3.08.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same period in the previous year, the company earned ($0.31) earnings per share. Research analysts anticipate that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of Cellectis during the 2nd quarter valued at approximately $29,000. First Affirmative Financial Network purchased a new stake in shares of Cellectis in the third quarter worth $45,000. Principal Financial Group Inc. raised its position in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC raised its position in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.